Nakamura Shotaro, Matsumoto Takayuki, Kitazono Takanari
Center for Advanced Medical Innovation, Kyushu University.
Nihon Rinsho. 2013 Aug;71(8):1424-8.
Clinical features and efficacy of Helicobacter pylori (H. pylori) eradication for patients with gastric MALT lymphoma are reviewed. Gastric MALT lymphoma comprises 1-5% of all gastric malignancies, while 40-50% of primary gastric lymphomas. In approximately 90% of cases, H. pylori infection plays the causative role in the pathogenesis, and H. pylori eradication is nowadays the first-line treatment for this disease, which leads to complete disease remission in 60-90% of cases. Predictive factors for resistance to eradication therapy include absence of H. pylori infection, deep invasion in the gastric wall, t(11:18)/API2-MALT1, and etc. Recently a large-scale Japanese multicenter study demonstrated that the long-term clinical outcome of gastric MALT lymphoma after H. pylori eradication is excellent.
本文综述了幽门螺杆菌（H. pylori）根除治疗对胃黏膜相关淋巴组织（MALT）淋巴瘤患者的临床特征及疗效。胃MALT淋巴瘤占所有胃恶性肿瘤的1%-5%，占原发性胃淋巴瘤的40%-50%。在大约90%的病例中，幽门螺杆菌感染在发病机制中起致病作用，目前幽门螺杆菌根除治疗是该病的一线治疗方法，60%-90%的病例可实现疾病完全缓解。根除治疗耐药的预测因素包括无幽门螺杆菌感染、胃壁深层浸润、t(11:18)/API2-MALT1等。最近一项日本大规模多中心研究表明，幽门螺杆菌根除治疗后胃MALT淋巴瘤的长期临床结局良好。
